Swaminathan Padmanabhan Iyer
Swaminathan Padmanabhan Iyer
Professor of Medicine, University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ...
Journal of Clinical Oncology 28 (10), 1749, 2010
6682010
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ...
Journal of Clinical Oncology 30 (6), 631-636, 2012
4862012
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
AMKC Chanan-Khan, LLD Musial, STK Padmanabhan, CWGDW Porter, ...
Journal of Clinical Oncology 24 (34), 5343-5349, 2006
4792006
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
WG Wierda, S Padmanabhan, GW Chan, IV Gupta, S Lisby, A Österborg, ...
Blood, The Journal of the American Society of Hematology 118 (19), 5126-5129, 2011
2212011
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
RT Swords, KR Kelly, PG Smith, JJ Garnsey, D Mahalingam, E Medina, ...
Blood 115 (18), 3796-3800, 2010
2042010
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
DM Benson Jr, CC Hofmeister, S Padmanabhan, A Suvannasankha, ...
Blood, The Journal of the American Society of Hematology 120 (22), 4324-4333, 2012
1972012
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ...
Leukemia 28 (11), 2155-2164, 2014
1842014
Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ...
Clinical Cancer Research 22 (4), 868-876, 2016
1562016
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
WG Wierda, TJ Kipps, J Dürig, L Griskevicius, S Stilgenbauer, J Mayer, ...
Blood, The Journal of the American Society of Hematology 117 (24), 6450-6458, 2011
1462011
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ...
Journal of hematology & oncology 7 (1), 11, 2014
1382014
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia
IM Ghobrial, F Hong, S Padmanabhan, A Badros, M Rourke, R Leduc, ...
Journal of Clinical Oncology 28 (8), 1422, 2010
1342010
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
1332019
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells
W Fiskus, S Sharma, J Qi, JA Valenta, LJ Schaub, B Shah, K Peth, ...
Molecular cancer therapeutics 13 (5), 1142-1154, 2014
1282014
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
IM Ghobrial, W Xie, S Padmanabhan, A Badros, M Rourke, R Leduc, ...
American journal of hematology 85 (9), 670-674, 2010
1262010
Allogeneic Vaccination With a B 7. 1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non-Small-Cell Lung Cancer
LE Raez, PA Cassileth, JJ Schlesselman, K Sridhar, S Padmanabhan, ...
Journal of Clinical Oncology 22 (14), 2800-2807, 2004
1242004
Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
LH Sehn, A Goy, FC Offner, G Martinelli, MD Caballero, O Gadeberg, ...
Journal of Clinical Oncology 33 (30), 3467, 2015
1232015
A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma …
SP Iyer, JT Beck, AK Stewart, J Shah, KR Kelly, R Isaacs, S Bilic, S Sen, ...
British journal of haematology 167 (3), 366-375, 2014
1002014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD
W Fiskus, S Sharma, J Qi, B Shah, SGT Devaraj, C Leveque, BP Portier, ...
Molecular cancer therapeutics 13 (10), 2315-2327, 2014
1002014
WTAP is a novel oncogenic protein in acute myeloid leukemia
H Bansal, Q Yihua, SP Iyer, S Ganapathy, D Proia, LO Penalva, PJ Uren, ...
Leukemia 28 (5), 1171-1174, 2014
892014
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
A Chanan‐Khan, KC Miller, D Lawrence, S Padmanabhan, A Miller, ...
Cancer 117 (10), 2127-2135, 2011
842011
The system can't perform the operation now. Try again later.
Articles 1–20